DDInter115 DDInter1628
Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Ardeparin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ardeparin {u} (Compound) binds {v} (Gene) SERPIND1
SERPIND1 {u} (Gene) regulates {v} (Gene) LBR
LBR {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Ardeparin {u} (Compound) binds {v} (Gene) SERPINC1
SERPINC1 {u} (Gene) regulates {v} (Gene) AKAP8L
AKAP8L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ardeparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} (Compound) binds {v} (Gene) JAK2
JAK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ardeparin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ardeparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ardeparin {u} may lead to a major life threatening interaction when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ardeparin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ardeparin {u} may lead to a major life threatening interaction when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Ardeparin {u} may lead to a major life threatening interaction when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ardeparin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Ardeparin (Compound) binds SERPIND1 (Gene) and SERPIND1 (Gene) regulates LBR (Gene) and LBR (Gene) is downregulated by Ruxolitinib (Compound)
Ardeparin (Compound) binds SERPINC1 (Gene) and SERPINC1 (Gene) regulates AKAP8L (Gene) and AKAP8L (Gene) is upregulated by Ruxolitinib (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) binds JAK2 (Gene) and JAK2 (Gene) is bound by Ruxolitinib (Compound)
Ardeparin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib (Compound) binds RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Ardeparin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Ardeparin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Ardeparin may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is downregulated by Ruxolitinib (Compound)
Ardeparin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)